Toward a Sustainable Development Community: Chery Group Leads the Future of Mobility Through Global ESG Action

Toward a Sustainable Development Community: Chery Group Leads the Future of Mobility Through Global ESG Action

WUHU, China, Oct. 22, 2025 /PRNewswire/ -- As the global automotive industry undergoes a century-defining transformation, a new era of openness and collaboration is emerging. Once a niche investment concept, Environmental, Social, and Governance...

Beatbot's Innovative Pool Robots Secure Prestigious 2025 GOOD DESIGN Award and IDEA Finalist

Beatbot's Innovative Pool Robots Secure Prestigious 2025 GOOD DESIGN Award and IDEA Finalist

RICHMOND, Texas, Oct. 22, 2025 /PRNewswire/ -- Beatbot, a global leader in cutting-edge robotic pool cleaning technology, continues its award-winning streak with the announcement that its iSkim Ultra and AquaSense 2 Ultra have received the 2025 GOOD...

Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma

Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma

SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, production, and commercialization of novel cell therapies, today...

Ampace Showcases More Economical and Efficient Energy Solutions at All Energy Australia 2025

Ampace Showcases More Economical and Efficient Energy Solutions at All Energy Australia 2025

MELBOURNE, Australia, Oct. 22, 2025 /PRNewswire/ -- Ampace will take the stage at All Energy Australia 2025 (Booth GG123), unveiling its latest advances in battery technology and next-generation energy storage solutions. As a trusted energy...

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of...

ENCAPS wins top honours at WRIQ's Lithium Battery Innovation Challenge

ENCAPS wins top honours at WRIQ's Lithium Battery Innovation Challenge

BRISBANE, Australia, Oct. 22, 2025 /PRNewswire/ -- The Waste Recycling Industry Association Queensland (WRIQ) has announced ENCAPS as the overall winner of the 2025 Lithium Battery Innovation Challenge, recognising its outstanding contribution to...

GAC at the Canton Fair: Exploring a New Collaborative Model of Globalization for Chinese Enterprises -- Products, Ecosystems, and Culture

GAC at the Canton Fair: Exploring a New Collaborative Model of Globalization for Chinese Enterprises -- Products, Ecosystems, and Culture

GAUNGZHOU, China, Oct. 20, 2025 /PRNewswire/ -- On October 15, as a leading force in China's automotive industry going global, GAC participated in the 138th Canton Fair under the theme "Where Craft Meets Technology." Blending Lingnan cultural...

The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC

The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC

After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P<0.0001). OS was significantly...

Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO

Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO

CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of...

Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity

Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity

- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of s mall m olecule GLP-1 receptor ( GLP-1R) a gonist ASC30 in 65 participants...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 17
  • menu
    menu